MARFRIG 3Q24 Review: A treasure in a clay pot



genial

Equity

Main takeaways:

(i) South America with accelerated shipments and exchange rate support with the devaluation of the BRL, volume of 219K; (ii) North America with sales volume of 508Kt, up +2.6% and -4.9%, reflecting favorable seasonality; (iii) Marfrig's consolidated results were once again weighed down by **BRF**'s good performance; (iv) Meat price pass-through scenario should not last; (v) Marfrig announces dividends and share cancellations; (vi) Our projections point to a leverage of 4.5xNet Debt/EBITDA in 2025; (vii) Even though from a fundamentalist point of view we don't agree with the way investors trade the company as proxy of BRF's performance, we still expect Marfrig's shares to rise in the trading session after the result, driven by the announcements cancellation of treasury shares and distribution of dividends with a strong yield (18%), due to BRF's excellent performance. We emphasize that this effect may be transitory, due to a flow of buyers who will dispose of the shares after the ex-dividend date. We therefore reiterate that, in our opinion, **this is not a good time** to set up long positions in the shares from a fundamentalist point of view, and we reiterate our **NEUTRAL rating** with a **12M Target Price** of **R\$14.35**, implying a **downside of -8.07%**.

Marfrig released its results yesterday, **November 13**, after the market closed. In our view, the company delivered **a reasonable quarter**, slightly above our estimates. When we look at BRF's figures from the standpoint of excluding consolidation, we still maintain our opinion that **the company lacks catalysts from a fundamentalist point of view**

3Q24 Review

South America: Acceleration in shipments, supported by the exchange rate. Marfrig's operations in South America posted net revenues of R\$4.3bn (+16.4% q/q; +28.9% y/y) and EBITDA of R\$517mn (+54.85% q/q; +8.2% y/y), with a margin of 12.1%. The volume of shipments reached 219Kt, in line with our estimates (+0.5% vs. Genial Est.), accelerating +15.1% q/q and +22.1% y/y. As we anticipated in our preview report, this performance was driven by (i) recent capacity additions and sustained by (ii) warmer demand, both domestically and abroad, given the gain in competitiveness due to the devaluation of the BRL/USD exchange rate. Domestic sales accounted for 60% of the volume, and China remained the main export destination, with 49% of the total.

Analysts

Igor Guedes +55 (11) 3206-8286 igor.guedes@genial.com.vc

Luca Vello +55 (11) 3206-1457 luca.vello@genial.com.vc

Isabelle Casaca +55 (11) 3206-8244 isabelle.casaca@genial.com.vc

Company

MRFG3 BZ Equity Neutral

Price: R\$ 15.61 (13-Nov-2024) Target Price 12M: R\$ 14.35 **North America: Margin compression continues.** The North American operation totaled a sales volume of 508Kt (+2.6% q/q; -4.9% y/y), reflecting the expected quarterly acceleration due to favorable seasonality during the summer period (barbecue season). The segment's net revenue was US\$3.2bn (+4.7% q/q; -3.9% y/y), while EBITDA fell to US\$79m, representing a contraction of -12.1% q/q and -47.1% y/y. The margin fell to 2.4% (-0.5p.p q/q; -2p.p y/y). In BRL, the ~6% devaluation of the BRL/USD favored the figures, with net revenue at R\$17.9b and EBITDA at R\$438.9mn.

Our Take on Marfrig

Results uploaded by BRF. BRF reported its results yesterday, October 13, reaching net revenue of R\$15.4b, up +3.8%t/t and +12.2%a/a. EBITDA came in at R\$2.9bn (+13.2% q/q; +138.6%a/a), above our estimates which were already more optimistic than the consensus, as we wrote in our report on the result (BRF 3Q24 Review: Let's talk about chicken!), contributing to Marfrig's consolidated net revenue of R\$37.7bn (69% contribution from BRF) and EBITDA of R\$3.9b (77% contribution from BRF).

Keeping an eye on the macro! In a scenario where the SELIC rate is expected to rise, we see disadvantages in investing in companies with high leverage, due to the increase in the cost of capital, which puts pressure on financial expenses and reduces net income, compromising the ability to generate shareholder value. Considering that the meatpackers sector is historically more leveraged, our preference is for companies with a better debt profile. In this context, we maintain our BUY recommendation for JBS and BRF, which have more controlled leverage and stronger fundamentals and are names with much lower leverage than Marfrig.

Passing on the price of meat in Brazil shouldn't last. The increase in the price of cattle seen in 3Q24 earlier than expected by the market was catalyzed by factors such as **(i)** an improvement in Brazilian income indicators, with a drop in unemployment and GDP growth, stimulating meat consumption; **(ii)** a higher volume of exports due to the favorable demand scenario and the devaluation of the BRL driving more, which resulted in large quantities of slaughter; and **(iii)** adverse weather conditions, with an exceptionally dry winter, leading ranchers to keep animals on pasture for longer, removing them from the slaughter pipeline and thus reducing supply

Market data shows that meatpackers had some ability to pass on costs to wholesalers in 4Q24, which was shown by the increase in the price of the boxed carcass. In turn, we saw that wholesalers passed on this increase to consumers, which was reflected in the IPCA with a 5.8% increase in the price of meat. However, we believe that these passthroughs are temporary, as meat prices tend to struggle to remain at high levels, given that consumers tend to trade down to more affordable proteins in boom scenarios.

Marfrig: announcement of dividends and cancellation of shares. The company announced two relevant facts yesterday, along with its results: (i) a dividend payment of R\$2.5bn, corresponding to R\$2.82/share, representing a yield of ~18%. This dividend is explained by BRF's results, and we question whether this is the company's best capital allocation decision, considering that they could keep this amount in cash to reduce leverage; (ii) cancellation of 20 million ordinary treasury shares, without reducing share capital, which we see as an effort by the company to generate shareholder value.

Leverage will decrease, but not by much. Marfrig has already received R\$1.5bn out of a total of R\$7.2bn from the sale of 13 assets to Minerva, with the remaining R\$5.7bn expected in 4Q24. The transaction took place at a multiple significantly higher than Marfrig's leverage ratio of 3.05x Net Debt/EBITDA in 2Q24, which provides some relief. However, we believe it will not be enough to solve the company's leverage challenges. Our projections indicate that Marfrig's leverage ratio should reach **4.5x Net Debt/EBITDA** in **2025**, even with BRF's contribution, which is above reasonable levels for the sector. This is due to the company's high level of debt and the reduction in slaughter capacity, especially in Brazil, resulting in lower EBITDA and making it difficult to reduce leverage.

A treasure in a clay pot. Market data indicates that the US beef cycle should remain **negative until at least 2Q27**, putting pressure on margins for a prolonged period. In Brazil, margins are also likely to be challenged due to the **reversal of the cycle**, with our estimates for the price of an arroba of beef at around R\$330 in 2025, compared to R\$239 on average in 3Q24. On the other hand, BRF's performance has been overwhelming, delivering successively above-consensus figures.

As a result, Marfrig's shares have had a high correlation with those of BRF, its subsidiary. We still see **Marfrig as the clay pot**, with many weaknesses in its investment thesis, and **BRF as the treasure**. With both markets (Brazil and the US) facing difficult cycles from 4Q24 onwards, Marfrig will find a hardship to manage its high leverage of **4.5x Net Debt/EBITDA** in **25E**. We therefore reiterate our **NEUTRAL rating**, with a **12M Target Price of R\$14.35**, which implies a **downside of -6.82%**.

Appendix: Marfrig

20245	20255	20265	20275
2024E	2025E	2026E	2027E
141,232	131,660	134,335	132,730
(128,239)	(119,942)	(121,708)	(120,855)
12,993	11,718	12,627	11,875
(4,071)	(3,454)	(4,363)	(5,387)
8,922	8,264	8,264	6,488
(1,454)	(1,609)	(1,654)	(1,730)
4,302	3,449	4,205	4,471
(2,384)	(2,100)	(2,619)	(1,971)
(1,291)	(1,035)	(1,262)	(1,341)
627	(314)	325	1,159
0,44%	-0,24%	0,24%	0,00%
	(128,239) 12,993 (4,071) 8,922 (1,454) 4,302 (2,384) (1,291) 627	141,232 131,660 (128,239) (119,942) 12,993 11,718 (4,071) (3,454) 8,922 8,264 (1,454) (1,609) 4,302 3,449 (2,384) (2,100) (1,291) (1,035) 627 (314)	141,232131,660134,335(128,239)(119,942)(121,708)12,99311,71812,627(4,071)(3,454)(4,363)8,9228,2648,264(1,454)(1,609)(1,654)4,3023,4494,205(2,384)(2,100)(2,619)(1,291)(1,035)(1,262)627(314)325

Figure 1. Marfrig – Income Statement in R\$ Millions (Genial Est. 2024-2027)

Figure 2. Marfrig- Cash Flow in R\$ Million (Genial Est. 2024-2027)

Cash Flow (FCFF)	2024E	2025E	2026E	2027E
Net Revenue	141,232	131,660	134,335	132,730
(-) COGS	(128,239)	(119,942)	(121,708)	(120,855)
Adjusted EBITDA	8,922	8,264	8,264	6,488
(-) D&A	(1,454)	(1,609)	(1,654)	(1,730)
EBIT	4,302	3,449	4,205	4,471
(-) Taxes	(1,291)	(1,035)	(1,262)	(1,341)
(+) D&A	1,454	1,609	1,654	1,730
(+/-) Δ WK	(3,576)	(3,576)	(3,576)	(3,576)
(-) Capex	(26)	(292)	(795)	(184)
FCFF	863	155	226	1,100

Disclosure Section

1. GENERAL DISCLAIMER

This report has been produced by the research department ("Genial Institutional Research") of Genial Institutional Corretora de Câmbio, Títulos e Valores Mobiliários S.A. ("GENIAL INSTITUTIONAL CCTVM"). Genial Institutional is a brand name of Genial Investimentos CCTVM.

Genial Rating		
	Definition	Coverage
Buy	Expected return above +10% in relation to the Company's sector average	49%
Neutral	Expected return between +10% and -10% relative to the Company's industry average	41%
Sell	Expected return below -10% in relation to the Company's sector average	5%
under Review	Under review	5%

This report may not be reproduced or redistributed to any other person, in whole or in part, for any purpose, without the prior written consent of GENIAL INSTITUTIONAL CCTVM. GENIAL INSTITUTIONAL CCTVM accepts no liability whatsoever for the actions of third parties in this respect.

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither GENIAL INSTITUTIONAL CCTVM nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report report

GENIAL INSTITUTIONAL CCTVM may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of GENIAL INSTITUTIONAL CCTVM.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by GENIAL INSTITUTIONAL CCTVM with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

The locally listed shares of Brazilian companies may only be purchased by investors outside of Brazil who are "eligible investors" within the meaning of applicable laws and regulations.

genial Research

2. ANALYST(S) DISCLOSURES AND CERTIFICATION

The principal analyst, IGOR GUEDES, is responsible for the content of this report and for meeting the requirements of Securities and Exchange Commission of Brazil (CVM) Instruction 598/2018.

The analysts hereby certify that the views expressed in this research report accurately reflect their personal views about the subject securities or issuers and it was prepared in an independent manner, including with respect to the person and to GENIAL INSTITUTIONAL.

The analyst hereby certifies that he (she) has no connection with any individual who works for the issuer(s) discussed in this report.

The analyst hereby certifies that he (she), or his (her) spouse or companion, either directly or indirectly, in his or her own name or on behalf of a third party, does not hold any of the securities covered in this report.

The analyst hereby certifies that he (she), or his (her) spouse or companion, is not directly or indirectly involved in the purchase, disposal or brokering of the securities covered in this report.

The analyst hereby certifies that he (she), or the his (her) spouse or companion, has no direct or indirect financial interest in the issuer covered in this report (other than trading shares in investment funds, in which the analyst cannot control, directly or indirectly, the administration or management of the fund, or which do not concentrate investments in sectors or companies that are covered by reports produced by the analyst).

The analyst's compensation is, directly or indirectly, determined by income from GENIAL INSTITUTIONAL's business and financial operations.

In addition, the analysts certify that no part of their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

The compensation of the analyst who prepared this report is determined by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues, however, compensation may relate to the revenues of GENIAL INSTITUTIONAL CCTVM, its affiliates and/or subsidiaries as a whole, of which investment banking, sales and trading are a part. Compensation paid to analysts is the sole responsibility of GENIAL INSTITUTIONAL CCTVM.

The analyst hereby certifies that he (she), or his (her) spouse or companion, does not serve as an officer, director, or advisory board member of the subject company.

The principal analyst is responsible for the content of this report and for meeting the requirements of Securities and Exchange Commission of Brazil (CVM) Instruction 598/2018.

Unless otherwise stated, the individuals listed on the cover page of this report are research analysts.



3. ADDITIONAL DISCLOSURE

- (i) This document was prepared by GENIAL INSTITUTIONAL Research and is hereby supplied for the sole purpose of providing information about companies and their securities.
- (ii) The information contained herein is provided for informational purposes only and does not constitute an offer to buy or sell, and should not be construed as a solicitation to acquire, any securities in any jurisdiction. The opinions expressed herein regarding the purchase, sale or holding of securities, or with respect to the weighting of such securities in a real or hypothetical portfolio, are based on careful analysis by the analysts who prepared this report and should not be construed by current or future investors as recommendations for any particular investment decision or action. The investor's final decision should be made considering all of the risks and fees involved. This report is based on information obtained from primary or secondary public sources, or directly from companies, and is combined with estimates and calculations prepared by GENIAL INSTITUTIONAL CCTVM. This report does not purport to be a complete statement of all material facts related to any company, industry, security or market strategy mentioned. The information has been obtained from sources believed to be reliable, but GENIAL INSTITUTIONAL CCTVM does not make any express or implied representation or warranty as to the completeness, reliability or accuracy of such information. The information, opinions, estimates and projections contained in this document are based on current data and are subject to change. Prices and availability of financial instruments are indicative only and subject to change without notice. GENIAL INSTITUTIONAL CCTVM is under no obligation to update or revise this document or to advise of any changes in such data.
- (iii) The securities discussed in this report, as well as the opinions and recommendations contained herein, may not be appropriate for every type of investor. This report does not take into account the investments objectives, financial situation or particular needs of any particular investor. Investors who wish to buy, sell or invest in securities that are covered in this report should seek independent financial advice that takes individual characteristics and needs into consideration, before making any investment decision with respect to the securities in question. Each investor should make independent investment decisions after carefully analyzing the risks, fees and commissions involved. If a financial instrument is denominated in a currency other than an investor's currency, changes in exchange rates may adversely affect the price or value of, or the income derived from the financial instrument, and the reader of this report assumes all foreign exchange risks. Income from financial instruments may vary, and therefore their price or value may rise or fall, either directly or indirectly. The information, opinions and recommendations contained in this report do not constitute and should not be interpreted as a promise or guarantee of a particular return on any investment. Past performance does not necessarily indicate future results, and no representation or warranty, express or implied, is made herein regarding future performance. Therefore, GENIAL INSTITUTIONAL CCTVM, its affiliated companies, and the analysts involved in this report take no responsibility for any direct, indirect or consequential loss resulting from the use of the information contained in this report, and anyone using this report undertakes to irrevocably indemnify GENIAL INSTITUTIONAL CCTVM and its affiliates from any claims and demands.
- (iv) Prices in this report are believed to be reliable as of the date on which this report was issued and are derived from one or more of the following: (i) sources as expressly specified alongside the relevant data; (ii) the quoted price on the main regulated market for the security in question; (iii) other public sources believed to be reliable; or (iv) GENIAL INSTITUTIONAL CCTVM's proprietary data or data available to GENIAL INSTITUTIONAL CCTVM.

- (v) No representation or warranty, either express or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein, except with respect to information concerning GENIAL INSTITUTIONAL CCTVM, its subsidiaries and affiliates. In all cases, investors should conduct their own investigation and analysis of such information before taking or omitting to take any action in relation to securities or markets that are analyzed in this report.
- (vi)GENIAL INSTITUTIONAL CCTVM makes no representations herein that investors will obtain profits. GENIAL INSTITUTIONAL CCTVM will not share with investors any investment profits nor accept any liability for any investment losses. Investments involve risks and investors should exercise prudence in making their investment decisions. GENIAL INSTITUTIONAL CCTVM accepts no fiduciary duties on behalf of recipients of this report and in communicating this report is not acting in a fiduciary capacity. This report is not to be relied upon in substitution for the exercise of recipient's independent judgment. Opinions, estimates, and projections expressed herein constitute the current judgment of the analyst responsible for the substance of this report as of the date on which the report was issued and are therefore subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of GENIAL INSTITUTIONAL CCTVM as a result of using different assumptions and criteria. The information, opinions and recommendations contained in this report do not constitute and should not be interpreted as a promise or guarantee of a particular return on any investment.
- (vii)Because the personal views of analysts may differ from one another, GENIAL INSTITUTIONAL CCTVM, its subsidiaries and affiliates may have issued or may issue reports that are inconsistent with, and/or reach different conclusions from, the information presented herein. Any such opinions, estimates, and projections must not be construed as a representation that the matters referred to therein will occur. Prices and availability of financial instruments are indicative only and subject to change without notice. Income from financial instruments may vary, and therefore their price or value may rise or fall, either directly or indirectly.
- (viii) This document may not be: (a) photocopied or duplicated in any manner, in whole or in part, and/or (b) distributed without GENIAL INSTITUTIONAL CCTVM's prior written consent. GENIAL INSTITUTIONAL CCTVM accepts no liability whatsoever for the actions of third parties in this respect.
- (ix)Neither GENIAL INSTITUTIONAL CCTVM nor any of its affiliates, nor any of their respective directors, employees or agents, accepts any liability for any loss or damage arising out of the use of all or any part of this report.
- (x) GENIAL INSTITUTIONAL CCTVM (or its affiliates, officers, directors or employees) may, to the extent permitted by law, have acted upon or used the information herein contained before the publication of this report and may have a position in securities issued by the companies mentioned herein and may make a market or act as a principal in any transactions in any such securities. Genial Institutional may from time to time perform investment banking or other services to, or solicit investment banking or other business from, the companies mentioned herein.



4. IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by Genial Institutional CCTVM, a company authorized to engage in securities activities in Brazil. Genial Institutional CCTVM is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and is not being provided pursuant to a soft-dollar arrangement.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Auerbach Grayson & Company LLC ("AGCO"), a registered broker dealer in the United States with an office at 20 West 55th Street New York, NY 10019, (212) 453-3523. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through Genial Institutional CCTVM.

If the report is to be distributed to anyone other than Major U.S. Institutional Investors in the United States. AGCO accepts responsibility for the contents of this report as provided for in relevant SEC releases and SEC staff no-action letters.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person at Auerbach Grayson & Company LLC ("AGCO") and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

The disclosures contained in research reports produced by GENIAL INSTITUTIONAL CCTVM and distributed by Auerbach Grayson & Company LLC ("AGCO") in the U.S. shall be governed by and construed in accordance with U.S. law. This report may not be reproduced or redistributed to any other person, in whole or in part, for any purpose, without the prior written consent of GENIAL INSTITUTIONAL CCTVM. Additional information relative to the financial instruments discussed in this report is available upon request.

UK Disclaimer:

(i) This document is STRICTLY CONFIDENTIAL to the recipient, may not be distributed to the press or other media and may not be reproduced in any form. this document is directed only at persons who are "INVESTMENT PROFESSIONALS" falling within article 19(5) of the FSMA 2000 (FINANCIAL PROMOTION) ORDER 2005, or HIGH NET WORTH BODIES falling within ARTICLE 49(2) of that order (together THE "RELEVANT PERSONS"). This document must not be acted on or relied on by persons who are not RELEVANT PERSONS.

(ii) The distribution of this document in other jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of any such other jurisdiction.

Copyright 2024 GENIAL GENIAL INSTITUTIONAL CCTVM